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Background: The role of single nucleotide polymorphisms (SNPs) of interleukin (IL)-28B in predicting therapeutic
response of pegylated interferon (peg-IFN) plus ribavirin (PR) for genotype 1 infected chronic hepatitis C patients
with advanced fibrosis (AF) is limited. The aim of this study is to assess its role in predicting sustained virologic
responses (SVR) to treatment.
Methods: Forty-two patients with biopsy proven hepatitis C virus (HCV) related AF (group A; Ishak fibrosis score, ≥4)
and 126 sex- and HCV genotype-matched patients without AF (group B; Ishak fibrosis score, ≤3) were recruited into
study. All patients received PR therapy for 24 weeks. Baseline and on-treatment clinical, virological and host factors
were evaluated for treatment efficacy.
Results: The SVR rate was significantly lower in group A than group B patients with genotype 1 infection (24% vs.
53.3%; p = 0.011). However, it was similar in those with genotype non-1 infection (76.5% vs. 76.5%; p = 1.0). IL-28B
rs8099917 genotype TT is the strongest predictor for SVR in genotype 1 infection. Patients who had TT genotype and
achieved RVR in group A had similar SVR rates with those in group B (44.4% vs. 53.3%; p = 0.614). One third of patients
in group A developed hematological adverse effects and had required modified doses during antiviral therapy.
Conclusions: In HCV genotype 1 infected AF receiving 24 weeks of PR treatment, patients with IL28B rs8099917
genotype TT, achieving RVR had similar SVR rate with those without AF. In contrast, patients with IL-28B rs8099917
non-TT genotype without achieving RVR are suggested to stop therapy.
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Chronic hepatitis C virus (HCV) infection causes im-
portant health problems worldwide and is an important
cause of morbidity and mortality from sequelae such as
liver cirrhosis and hepatocellular carcinoma (HCC) [1-3].
In patients with HCV-related cirrhosis, the annual inci-
dence rate of developing hepatic decompensation and
HCC are 3.9% and 1.4–8%, respectively [3-5]. The main
goals of therapy in patients with HCV-related cirrhosis are* Correspondence: ronald@adm.cgmh.org.tw
1Liver Research Unit, Chang Gung Memorial Hospital, 222 Mai-Chin Road,
Keelung 20401, Taiwan
Full list of author information is available at the end of the article
© 2015 Hu et al.; licensee BioMed Central. Thi
Attribution License (http://creativecommons.o
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.to eradicate HCV, improve liver histologic activity, and re-
duce fibrosis. In addition, several studies have shown that
chronic HCV infected patients with advanced fibrosis
(AF) achieving SVR after interferon-based therapy have
reduced risks of developing liver decompensation, HCC,
and liver-related mortality [6-12]. Therefore, although
these patients were considered to be a difficult-to-treat
population with less tolerability and poor therapeutic re-
sponses to pegylated interferon plus ribavirin (PR) therapy
[13,14], they could still benefit from the treatment with a
lower risk of liver disease progression and liver-related
complications. The data of the efficacy and safety of PR
therapy in HCV-infected patients with AF [11,15-17] iss is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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evaluate the beneficial effect and safety of PR therapy in
patients with HCV-related AF. Baseline and on-treatment
clinical, virological and host factors were also evaluated
for predictors of SVR.
Methods
Study population
From October 2003 to January 2011, we prospectively
enrolled 168 consecutive treatment-naïve patients with
biopsy proven chronic HCV infection into the study. AF
was defined as a fibrosis score ≥4 on the Ishak modifica-
tion of histologic activity index. Forty-two patients with
AF were stratified as the study group (group A). Another
126 age-, sex-, and genotype-matches (1 vs. non-1) pa-
tients without AF (fibrosis scores ≤3 on the Ishak modi-
fication scores), were stratified as the control group
(group B). None of the patients had received antiviral
therapy before enrollment in this study. Patients with
concurrent hepatitis B virus infection, toxic hepatitis,
autoimmune hepatitis, primary biliary cirrhosis, or Wilson’s
disease were excluded from this study. Patients with evi-
dence of decompensated liver cirrhosis, chronic alcohol
abuse, and psychiatric problems were also excluded.
All 168 patients received weekly peg-IFN injections
plus daily oral RBV for 24 weeks. The prescribed pegIFN
regimen consisted of pegIFN alfa-2a 180 μg or weight-
based pegIFN alfa-2b 1.5 μg/kg. For genotype 1 (GT1)
HCV-infected patients, the RBV dose was 1000 mg/day
for those body weight (BW) <75 kg or 1200 mg for those
with BW ≥ 75 kg. For genotype non-1 HCV-infected pa-
tients, the RBV dose was 800 mg/day. All patients were
followed up for 24 weeks after the completion of the treat-
ment. During the treatment period, patients had weekly
outpatient visits during the first 4 weeks and visits bi-
weekly between the 5th and 24th weeks. Hematological
and liver biochemical tests were conducted during each
visit. The HCV RNA levels were evaluated before the initi-
ation of the treatment, at week 4, week 12, the end of the
treatment (EOT) and 24 weeks after the completion of the
treatment (end of follow-up; EOFU). All biochemical and
virologic tests were performed in the clinical laboratories
of Chang Gung Memorial Hospital. The degree of hepatic
inflammation and fibrosis was graded using an Ishak
modified scores and read by a single pathologist (Dr.
Chang LC). Adverse events related to the PR therapy were
also recorded at each visit. Patients who received more
than 80% of the recommended PR dosage for more than
80% of the expected treatment period were defined as
having 80/80/80 adherence [18]. Informed consent was
obtained from all the patients enrolled in this study. The
study was performed in accordance with the ethical guide-
lines of the International Conference on Harmonisation
for Good Clinical Practice and has been approved by theInstitutional Review Board of Chang Gung Memorial
Hospital (No. 99–3012C).
Tests for hepatitis C virus and IL-28B genotyping
Anti-HCV tests were conducted using a third-generation
enzyme immunoassay kit (AxSYM® HCV Version 3.0;
Abbott Laboratories, Berkshire, UK). Serum HCV RNA
was quantified using a real-time polymerase chain reac-
tion (PCR) assay (COBAS® AmpliPrep Instrument and
COBAS® TaqMan® 48; Roche Molecular Systems, Inc.,
Branchburg, USA), with a detection limit of 15 IU/mL.
HCV genotyping was determined using a linear probe
assay (VERSANT™ HCV Genotype Assay (LiPA); Bayer
Corporation, Tarrytown, NY, USA).
The interleukin-28B (IL-28B) gene single-nucleotide
polymorphism (SNP), rs8099917 and rs12979860, were
chosen according to previous reports [19-22]. The two
SNPs, rs8099917 T/G and rs12979860 C/T, gene poly-
morphism were genotyped using PCR and specific primers
as described previously [23]. The sequences were obtained
from the National Center for Biotechnology Information
Entrez SNP Database.
Assessment of the efficacy of PR therapy
Rapid virologic response (RVR) was defined as undetect-
able serum HCV RNA by using PCR at the end of week
4 of therapy. Complete early virologic response (cEVR)
was defined as undetectable serum HCV RNA at
12 weeks of therapy. The treatment efficacy was evalu-
ated after 24 weeks of PR therapy (EOT) and after
24 weeks of follow-up (EOFU). SVR was defined as
achievement of undetectable serum HCV RNA by using
PCR at the EOT that was sustained after the EOFU.
Statistical analysis
The statistic test is equivalent in form to a Chi-square
test statistic. Specifically for patients with AF, a continu-
ity corrected Chi-square test with a 0.025 two-sided sig-
nificance level will have 80% power to detect a 25%
difference between patients with and without AF. As-
suming the test arm has a SVR rate of 44% and the con-
trol arm has a SVR rate of 70%, the sample size in each
group is 36 and 109 when the allocation ratio of control
arm to test arm is 3. After adjusted a 10% withdrawal
rate of this study, the final sample size will be 40 and
120 of each groups.
Evaluation of the efficacy of PR therapy was assessed
using intention-to-treat (ITT) analysis. For ITT analysis,
patients who received more than one dose of peg-IFN
were enrolled, and drug discontinuation was defined as
discontinuation of the treatment without completing
80% of the expected dosage. The continuous variables
were expressed as mean ± standard deviation (SD) values,
and two-tailed Student’s unpaired t-test was used to
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ences between groups of categorical variables were analyzed
using chi-square test or Fisher’s exact test. The significant
factors were then subjected to multivariate analysis with
stepwise logistic regression model to test for interactions
between the different significant covariates. A p value <0.05
was considered statistically significant. The statistical ana-
lyses were performed using the SPSS ver. 12.0 software
(SPSS Inc., Chicago, USA).
Results
Demographic and clinical characteristics
The baseline characteristics of the 168 patients are listed
in Table 1. Of them, 42 (25%) with liver histology show-
ing AF was assigned to group A. The other 126 (75%)
without AF was assigned to group B. Women (57.1%)
and HCV GT1 infection (59.5%) were predominant. Most
of the demographic and virologic characteristics and treat-
ment regimens were similar in both groups; however, the
total bilirubin level in group A was greater than that in
group B (1.2 ± 0.5 vs. 1.0 ± 0.4 mg/dL, p = 0.03). TheTable 1 Patient demographic characteristics
Characteristic Group A
(n = 42)
Age (years)† 60.5 ± 8.5
Male sex‡ 18 (42.9)
Genotype 1‡ 25 (59.5)
Fatty liver‡ 12 (28.6)
Body weight (kg)† 61.7 ± 7.0
Body mass index (kg/m2)† 24.9 ± 2.5
Necroinflammatory scores† 6.3 ± 2.0
Creatinine (mg/dL)† 0.9 ± 0.3
AST (U/L)† 99.2 ± 43.8
ALT (U/L)† 119.8 ± 62.4
AFP (ng/mL)† 45.5 ± 96.4
Albumin (g/dL)† 3.8 ± 0.5
Total bilirubin (mg/dL)† 1.2 ± 0.5
White blood cell s (×103/μL)† 5.5 ± 1.9
Hemoglobin level (g/dL)† 13.5 ± 1.8
Platelet count (×103/μL)† 129.6 ± 47.3
HCV RNA (IU/mL)† 1.81 ± 2.00 ×10
Low viral load‡ 14 (33.3)
rs8099917 (TT)‡ 33/40 (82.5)
rs12979860 (CC)‡ 34/40 (85)
Ribavirin per body weight (mg/kg)† 15.7 ± 2.9
HCV, hepatitis C virus; AST, aspartate aminotransferase; ALT, alanine aminotransfera
Low viral load, HCV RNA ≤800,000 IU/mL.
†mean ± SD; ‡no. (%).
Group A, patients with Ishak fibrosis score 4–6.
Group B, patients with Ishak fibrosis score 0–3.pretreatment albumin level (3.8 ± 0.5 vs. 4.2 ± 0.4 g/dL;
p = 0.001), hemoglobin level (13.5 ± 1.8 vs. 14.2 ± 1.6
g/dL; p = 0.03), and platelet counts (129.7 ± 47.3 × 103
vs. 177.9 ± 56.7 × 103 platelets/μL; p < 0.001) were lower
in group A in comparison with those in group B. There
were fewer patients with fatty liver in group A than in
group B (28.6% vs. 47.6%; p = 0.03). The pretreatment
viral loads of HCV genotype 1 infected patients in group
A and group B are 2.32 ± 2.37×106 and 2.54 ± 8.49 ×
106 IU/ml, respectively (p = 0.9). The pretreatment viral
loads of HCV genotype non-1 infected patients in group
A and group B are 1.07 ± 0.89 × 106 and 1.85 ± 4.86 ×
106 IU/ml, respectively (p = 0.52). Among HCV geno-
type 1 infected patients, 10 patients (40%) in group A
and 34 patients (45%) in group B had a serum HCV
RNA viral load of less than 8 × 105 IU/mL (p = 0.78).
Among HCV genotype non-1 infected patients, 7 pa-
tients (41%) in group A and 23 patients (45%) in group
B had a serum HCV RNA viral load of less than 8 ×
105 IU/mL (p = 0.78).There were 164 (97%) and 166
(99%) samples available for IL28B rs8099917 andGroup B p-Value
(n = 126)




61.3 ± 10.3 0.75
24.6 ± 3.2 0.59
6.0 ± 1.9 0.31
0.9 ± 0.6 0.81
94.4 ± 62.8 0.65
137.1 ± 103.6 0.197
16.9 ± 42.6 0.08
4.2 ± 0.4 0.001
1.0 ± 0.4 0.03
5.8 ± 1.7 0.33
14.2 ± 1.6 0.03
177.0 ± 54.7 <0.001




16.3 ± 2.7 0.19
se; AFP, α-fetoprotein.
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TT and CC genotype were 87% and 89%, respectively.
Virologic responses to treatment
After PR treatment, 67.5% and 90.9% of the patients
achieved RVR and cEVR, respectively (Table 2). With re-
spect to on-treatment responses, the RVR rates in
groups A and B were similar (58.3% vs. 70.4%; p =
0.176). However, less cEVR was achieved in group A
than in group B (81.1% vs. 94%; p = 0.017). After stratify-
ing data on the basis of the HCV genotype (GT1 and
non-1), the difference between these two groups was
mainly observed in HCV GT1 infected patients (68.2%
vs. 89.9%; p = 0.014).
At EOFU, 98 (58.3%) achieved SVR. The SVR rate was
lower of patients with AF (45.2% vs. 69.7%; p = 0.047).
Among patients with HCV GT1, the SVR rate was sig-
nificantly lower in group A than group B (24% vs. 53.3%;
p = 0.011). In contrast, in patients infected with HCV
genotype non-1, the SVR rate was quite similar between
these two groups (76.5% vs. 76.5%; p = 1.0). The SVRTable 2 Virologic responses of the different fibrosis groups
Response Overall Gro
HCV genotype n/N (%) n/N
RVR 102/151 (67.5) 21/
1 50/91 (54.9) 9/2
Non-1 52/60 (86.7) 12/
cEVR 140/154 (90.9) 30/
1 77/91 (84.6) 15/
Non-1 63/63 (100) 15/
ETR 148/168 (88.1) 36/
1 84/100 (84) 21/
Non-1 64/68 (94.1) 15/
SVR 98/168 (58.3) 19/
1 46/100 (46) 6/2
Non-1 53/68 (76.5) 13/
SVR (with RVR) 77/102 (75.5) 14/
1 35/50 (70) 4/9
Non-1 42/52 (80.8) 10/
Relapse 50/148 (33.8) 17/
1 38/84 (45.2)# 15/
Non-1 12/64 (18.8)# 2/1
Discontinuation 13/168 (7.7) 6/4
1 8/100 (8) 3/2
Non-1 5/68 (7.4) 3/1
n, number of patients with response; N, total number of patients in the group.
HCV, hepatitis C virus; RVR, rapid virologic response; cEVR, complete early virologic
Group A, patients with Ishak fibrosis score 4–6.
Group B, patients with Ishak fibrosis score 0–3.
*p = 0.001; **p = 0.008, #p = 0.001.rate was substantially higher in patients infected with
HCV genotype non-1 than those in GT1 in both groups
(GT1 vs. non-1; 24% vs. 76.5% in group A, p = 0.001,
and 53.3% vs. 76.5% in group B, p = 0.008).
The relapse rate was significantly higher among pa-
tients with HCV GT1 infection than those infected by
HCV genotype non-1 (45.2% vs. 18.8%; p = 0.001). The
relapse rate was also higher in group A than in group B
(47.2% vs. 29.5%; p = 0.05) (Table 2). Among HCV geno-
type non-1 infected patients, the relapse rates were simi-
lar in both groups (13.3% vs. 20.4%; p = 0.539). However,
HCV GT1-infected patients with AF showed higher
relapse rates than those without AF (71.4% vs. 36.5%;
p = 0.005).
Predictors for SVR in HCV GT1 infected patients
In HCV GT1 infection, univariate analysis showed that
baseline factors, younger age, male gender, pretreatment
lower HCV RNA level, RVR, absence of AF, presence of
fatty liver, higher alanine aminotransferase (ALT) levels,
higher hemoglobin and platelet counts, and IL-28B SNPup A Group B
(%) n/N (%) p-value
36 (58.3) 81/115 (70.4) 0.176
2 (40.9) 41/69 (59.4) 0.129
14 (85.7) 40/46 (87) 0.9.5
37 (81.1) 110/117 (94) 0.017
22 (68.2) 62/69 (89.9) 0.014
15 (100) 48/48 (100) –
42 (85.7) 112/126 (88.9) 0.582
25 (84) 63/75 (84) 1
17 (88.2) 49/51 (96.1) 0.234
42 (45.2) 79/126 (69.7) 0.047
5 (24)* 40/75 (53.3)** 0.011
17 (76.5)* 39/51 (76.5)** 1.0
21 (66.7) 63/81 (77.8) 0.291
(44.4) 31/41 (75.6) 0.065
12 (83.3) 32/40 (80) 0.797
36 (47.2) 33/112 (29.5) 0.05
21 (71.4) 23/63 (36.5) 0.005
5 (13.3) 10/49 (20.4) 0.539
2 (14.3) 7/126 (5.6) 0.067
5 (12) 5/75 (6.7) 0.395
7 (17.6) 2/51 (3.9) 0.06
response; ETR, end of treatment response; SVR, sustained virologic response.
Table 3 Factors predicting a sustained virologic response in HCV genotype 1-infected patients by univariate & multivariate
analysis
Factors Univariate Multivariate
OR 95% CI p-Value OR 95% CI p-Value
Age (years) 0.925 0.877–0.976 0.005 0.897 0.830–0.969 0.006
Male gender 3.694 1.819–6.912 0.002 4.813 1.512–15.324 0.008
Low viral load 2.6 1.154–5.858 0.021
RVR 7.233 2.84–18.422 <0.001 6.853 2.142–21.931 0.001
No advanced fibrosis (F1-3) 3.619 1.3–10.075 0.014 4.403 1.166–16.625 0.029
Fatty live 3.087 1.353–7.047 0.007
rs8099917 TT vs. non-TT 13.2 1.642–106.13 0.015 13.422 1.277–141.553 0.031
ALT (U/L) 1.005 1.000–1.011 0.049
Hemoglobin (mg/dL) 1.349 1.058–1.72 0.016
Platelet count (×103/μL) 1.012 1.003–1.021 0.007
HCV, hepatitis C virus; OR, Odds Ratio; CI, confidence interval; Low viral load, HCV RNA ≤800,000 IU/mL; RVR, rapid virologic response; ALT, alanine aminotransferase.
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Multivariate analysis demonstrated that IL-28B rs8099917
genotype TT is the strongest predictor for SVR (odds ratio
[OR] = 13.422; 95% confidence interval [CI], 1.277 –
141.53; p < 0.031), followed by achieving RVR (OR = 6.853;
95% CI, 2.142 – 21.931; p = 0.001), male gender (OR =
4.813; 95% CI, 1.512 – 15.324; p = 0.008), absence of AF
(OR = 4.403; 95% CI, 1.166 – 16.625; p = 0.029), and
younger age (OR = 0.897 per 1 year increase; 95% CI,
0.83 – 0.969; p = 0.006).
Influence of achieving RVR and IL28B rs8099917 TT
genotype on SVR rates in HCV GT1 infected patients with AF
A higher SVR rate (44.4%) was obtained from HCV
GT1-infected group A patients who achieved an RVR.
All the nine patients achieving RVR had favorable IL28B
rs8099917 TT allele. The sensitivity, specificity, positive
predictive value (PPV) and negative predictive value
(NPV) of achieving RVR for SVR were 67%, 69%, 44%
and 85%, respectively (Table 4). With regard to IL28B
rs8099917 genotype, the HCV GT1-infected patients in
group A with TT allele obtained a SVR rate of 31.6%.
The sensitivity, specificity, PPV and NPV of an IL28B
rs8099917 TT genotype for SVR were 100%, 22%, 30%
and 100%, respectively. None of the patients with
rs8099917 non-TT genotype achieved an RVR and SVR.Table 4 IL28B rs8099917 TT allele and rapid virological
response in predicting sustained virological response
Sensitivity Specificity PPV NPV
AF(+) rs8099917 100% 22% 30% 100%
RVR (+) 67% 69% 44% 85%
AF(−) rs8099917 97% 24% 59% 89%
RVR (+) 80% 67% 80% 71%
AF, advanced fibrosis; RVR, rapid virologic response.
PPV, positive predictive value; NPV, negative predictive value.Adverse events and discontinuation of treatment
Six patients (14.3%) in group A and 7 patients (5.6%) in
group B discontinued the therapy because of intolerance
to treatment-related adverse effects. The withdrawal
rates were slightly higher in the group A with marginal
significance (14.3% in group A vs. 5.6% in group B; p =
0.067). Half of patients who discontinued the treatment
did so within the first 2 months (50% vs.57%, in groups
A and B, respectively). More patients with AF had re-
duced the regimen dose due to adverse effects (33% of
group A vs. 15% of group B; p = 0.01). In our study, the
main clinical adverse effects that developed during ther-
apy included pruritus (38%), malaise (36%), insomnia
(30%), anorexia (28%), dizziness (27%), fever (24%), dys-
pnea (23%), and myalgia (23%) (Table 5). The incidences
of adverse events were similar between the 2 groups; how-
ever, more patients in group A had hematological adverse
effects such as thrombocytopenia (26% of group A vs. 6%
of group B; p < 0.001) and anemia (31% vs. 16%, in groups
A and B, p = 0.033). Eleven patients (26%) in group A and
17 patients (13%) in group B needed erythropoietin ther-
apy because of symptomatic anemia.
Discussion
AF has been considered a strong negative predictor for
SVR in PR combination treatment. There has been a lot
of debate on the use of this combination therapy to treat
patients with AF, because of a high frequency of adverse
effects, a high rate of treatment discontinuation, and
decreased SVR. Previous studies have shown that an
overall SVR rate for patients with AF is 30–52%, but
most of these results were obtained from subgroup ana-
lysis composed of only a small number of patients in
large clinical trials [24,25].
Our analysis shows that HCV genotype is an import-
ant predictor for SVR. When the HCV genotypes are
Table 5 Rates of adverse events during treatment
Adverse effects Patients with
advanced fibrosis
(n) (%) (N =42)
Patients without
advanced fibrosis
(n) (%) (N =126)
Dose modification 14 (33)* 19 (15)*
PegIFN 2 (5) 2 (2)
RBV 12 (29) 19 (15)
General disorder
Fatigue 15 (36) 47 (37)
Fever 9 (21) 31 (25)
Rigor 7 (17) 15 (12)
Headache 4 (10) 15 (12)
Asthenia 4 (10) 10 (8)
Dizziness 11 (26) 34 (27)
Weight loss 0 (0) 5 (4)
Gastrointestinal effects
Abdominal pain 9 (21) 25 (20)
Anorexia 15 (36) 32 (26)
Nausea 3 (7) 10 (8)
Vomiting 0 (0) 5 (4)
Diarrhea 3 (7) 6 (5)
Constipation 1 (2) 3 (2)
Psychiatric effects
Depression 2 (5) 15 (12)
Insomnia 15 (36) 35 (28)
Anxiety 2 (5) 3 (2)
Respiratory effects
Cough 8 (19) 26 (21)
Dyspnea 13 (31) 25 (20)
Rhinorrhea 0 (0) 7 (6)
Sore throat 2 (5) 6 (5)
Epistaxis 0 (0) 3 (2)
Neuromuscular effects
Myalgia 11 (26) 28 (22)
Arthralgia 2 (5) 6 (5)
Numbness 2 (5) 6 (5)
Dermatologic effects
Pruritus 18 (43) 46 (37)
Alopecia 6 (14) 18 (14)
Rash 8 (21) 19 (15)
Dry skin 2 (5) 2 (2)
Injection site irritation 0 (0) 2 (2)
Table 5 Rates of adverse events during treatment
(Continued)
Hematologic effects
Anemiaa 13 (31)** 20 (16)**
Leukopeniab 5 (12) 8 (6)
Thrombocytopeniac 11 (26)*** 7 (6)***
EPO 11 (26) 17 (14)
BT 3 (7) 5 (4)
EPO, erythropoietin; BT, blood transfusion.
*p = 0.01; **p < 0.05; ***P < 0.001.
ahemoglobin level <8.5 g/dL.
bwhite blood cell count <1500 cells/mm3.
cplatelet count <50,000 cells/mm.
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tients with AF is observed only in those infected with
HCV GT1 (group A vs. group B, 24.9% vs. 53.5%; p =
0.011) and not in those infected with HCV genotype
non-1 (76.5% vs. 76.5%; p = 1.0). Indeed, low treatment
response rates have been reported in other studies of PR
treatment for HCV GT1, treatment-naive patients with
AF; the SVR rates were reported to be around 15–40%
[15,16,26-29]. Thus, HCV genotype non-1–infected pa-
tients with AF should be encouraged to receive the PR
therapy because they seem to show an optimal response
to the therapy.
Genetic polymorphism near the IL28B gene on
chromosome 19 (rs 12979860 and rs8099917), encoding
interferon-λ-3 (IFN-λ-3), was shown to be important
predictors for SVR to PR treatment in chronic hepatitis
C infection [19-22,30]. However, rare reports had stud-
ied its role in HCV-related cirrhotic patients receiving
PR therapy. Shakado et al. [31] had demonstrated that
patients with the rs8099917 TT allele had significant
higher SVR rate than those with rs8099917 TG or GG
allele (37.0% vs. 20.8%; p = 0.013). In our study, IL28B
rs8099917 TT genotype was demonstrated to be the
strongest predictor for SVR rate in HCV GT1–infected
patient. In HCV GT1–infected patients with rs8099917
TT genotype, a SVR rate of 30% was obtained in those
with AF, which was lower than that of those without AF
(30% vs. 59%; p = 0.022). However, if the patients with
HCV GT1 infection in group A had a rs8099917 TT
genotype and achieved an RVR, a high SVR rate of
44.4% could be obtained, which was comparable to the
overall SVR rates of the patients with HCV GT1 infec-
tion in group B (44.4% vs. 53.3%; p = 0.614).
In this study, we also found that none of the patients
with AF and rs8099917 non-TT genotype achieved an
RVR, and all of them failed to have a SVR. Thus, IL28B
genotyping can be taken into consideration when deter-
mining whether a cirrhotic patient will receive PR ther-
apy. The IL28B rs8099917 genotype had a 100% negative
predictive value (NPV) of HCV GT1 infected patients
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study suggested that don’t treat HCV GT1 infected pa-
tient with AF who was IL28B rs 8099917 non-TT geno-
type using PR reagents. In addition, the PR therapy can
be stopped in HCV GT1 infected patient with AF who
did not achieve an RVR during the treatment.
The combination of PR is associated with many adverse
effects and is thought to be tolerated less by patients
with AF than those without AF. In addition, safety is
a major concern for these patients because portal
hypertension-related splenomegaly increases the risk
for cytopenia, including anemia, thrombocytopenia, and
neutropenia [32-34]. However, in the present study, the
rates of common side effects that developed during anti-
viral treatment were similar in patients with and without
AF, except that more hematological adverse events happen
to patients with AF. Those patients had more symptom-
atic anemia with increased need of subcutaneous erythro-
poietin supplement. However, the proportion of patients
that discontinued therapy due to severe adverse events
was similar between the 2 groups (group A vs. group B,
5% vs. 1%; p = 0.155). This findings suggest that PR
treatment are well-tolerated by the chronic HCV-infected
patients with AF in Taiwan.
Direct-acting antiviral agents (DAAs) are potential
novel therapies that specifically target HCV (STAT-C)
enzymes involved in viral replication or viral entry into
the host cell (e.g., proteases and polymerases). Recent
report of sofosbuvir (a kind of HCV NS5B polymerase
nucleotide inhibitor) based therapy in treating cirrhotic
patients has shown a 80% SVR rate at week 12 in
treatment-naïve HCV GT1 infected patients when sofos-
buvir is combined with pegIFN plus RBV therapy for
12 weeks [35]. Among HCV genotype-2/3 infected pa-
tients with cirrhosis, the SVR rate was 66% with 16-
week sofosbuvir plus RBV combination therapy [36].
This new approach with DAAs in treating difficult-to-
treat patients offers an important milestone in HCV
therapy and might replace pegIFN as the mainstream of
HCV treatment in the future.
The first limitation of present study is that the treatment
duration in both groups is 24 weeks. This is too short in
GT1 HCV-infected patients, especially in those with high
viral load (>8.0 × 5 log IU/mL), regardless of reaching
RVR or not. This treatment duration was stipulated in the
reimbursement policy of the National Health Insurance in
Taiwan at that time, but treatment duration is now deter-
mined by response to therapy. The second limitation is
the small case numbers in present study, especially those
with biopsy proven AF. However, in view of the indication
for antiviral therapy is no longer necessary to perform
liver biopsy before treatment, the present report is more
important to emphasize the therapeutic efficacy and the
underlying hepatic fibrosis evaluated by liver biopsyConclusions
PR combination therapy is an effective treatment for
HCV genotype non 1-infected patients with AF. With
respect to HCV GT1–infected AF patients, showing IL-
28B rs8099917 genotype TT and achieving RVR have a
comparable SVR rate to those without AF. In HCV GT1
with AF, IL-28B rs8099917 non-TT genotype, PR is not
the drug of choice. Waiting for DAA plus PR or IFN-
free therapy is highly recommended. Furthermore, HCV
GT1 patients with AF and failed to achieve an RVR, PR
therapy should be stopped earlier. Otherwise, patients
with AF should be encouraged to receive antiviral therapy
aggressively, particularly in those with HCV genotype non-
1, or GT1 with IL-28B TTallele and achieving an RVR.
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